Proof-of-concept studies with a computationally designed Mpro inhibitor as a synergistic combination regimen alternative to Paxlovid.
Papini C, Ullah I, Ranjan AP, Zhang S, Wu Q, Spasov KA, Zhang C, Mothes W, Crawford JM, Lindenbach BD, Uchil PD, Kumar P, Jorgensen WL, Anderson KS.
Papini C, et al. Among authors: anderson ks.
Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2320713121. doi: 10.1073/pnas.2320713121. Epub 2024 Apr 15.
Proc Natl Acad Sci U S A. 2024.
PMID: 38621119
Free PMC article.